본문 바로가기

카테고리 없음

Immune Thrombocytopenia

Immune Thrombocytopenia

The Immune Thrombocytopenia market size in the 7MM was approximately USD 2,527.72 million in 2017.  The United States accounts for the largest ITP market size.

 

Prospective trials, by several pharma companies including Octapharma USA, Amgen, CSL Behring, Dova Pharmaceuticals, Rigel Pharmaceuticals, Zenyaku Kogyo/Biogen Idec, Novartis, Takeda, AstraZeneca, Biotest, GC Pharma, SK Plasma, Argenx, Kezar Life Sciences, UCB Biopharma, Bristol-Myers Squibb, Principia Biopharma, and Protalex, are underway that may be able to enhance the approach and improve overall outcomes in ITP patients in upcoming years.

 

There are many pipeline therapies under development in the Immune thrombocytopenia market; and with the expected launch of upcoming therapies the ITP market is expected to experience significant growth.


For more detailed information visit: https://www.delveinsight.com/blog/immune-thrombocytopenia-market/